SCHEMBL230366

SCHEMBL230366

COC(=O)c1cc(Nc2ccc(Cl)cc2)cc(C(=O)c2ccc(Nc3ccc(Cl)cc3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
ALDH1A1 P00352 3/20 0.49
LMNA P02545 2/20 0.49
HPGD P15428 4/20 0.49
KDR P35968 1/20 0.48
XBP1 P17861 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 2/20 0.47
DHODH Q02127 1/20 0.46
ATM Q13315 1/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
KDM4E B2RXH2 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230254 0.90 MAPT (0.49) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL27334844 0.87 MAPT (0.52) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL229926 0.86 MEN1 (0.57) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL232108 0.85 MAPT (0.44) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL232107 0.85 CA1 (0.57) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL28266243 0.84 DHODH (0.58) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL231402 0.83 SRD5A2 (0.59) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL3297101 0.81 HPGD (0.66) MAPTNPC1RAB9AALDH1A1LMNA
SCHEMBL559181 0.79 MAPT (0.47) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL5928751 0.79 RAB9A (0.74) MAPTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406220-A1 BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS Biolipox AB (SE) 2012-01-18 EP disclosed
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
WO-2010103279-A1 BIS AROMATIC COMPOUNDS FOR USE AS LCT4 SYNTHASE INHIBITORS BIOLIPOX AB (SE) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R MAPT 4117/4885NPC1 2560/4885RAB9A 3916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.